Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro

Valeria Cagno1,2,6, Chiara Medaglia1,6, Andreas Cerny1, Thomas Cerny4, Arnaud Charles-Antoine Zwygart1, Erich Cerny5,6* & Caroline Tapparel1,6*

Methylene blue is an FDA (Food and Drug Administration) and EMA (European Medicines Agency) approved drug with an excellent safety profile. It displays broad-spectrum virucidal activity in the presence of UV light and has been shown to be effective in inactivating various viruses in blood products prior to transfusions. In addition, its use has been validated for methemoglobinemia and malaria treatment. In this study, we first evaluated the virucidal activity of methylene blue against influenza virus H1N1 upon different incubation times and in the presence or absence of light activation, and then against SARS-CoV-2. We further assessed the therapeutic activity of methylene blue by administering it to cells previously infected with SARS-CoV-2. Finally, we examined the effect of co-administration of the drug together with immune serum. Our findings reveal that methylene blue displays virucidal preventive or therapeutic activity against influenza virus H1N1 and SARS-CoV-2 at low micromolar concentrations and in the absence of UV-activation. We also confirm that MB antiviral activity is based on several mechanisms of action as the extent of genomic RNA degradation is higher in presence of light and after long exposure. Our work supports the interest of testing methylene blue in clinical studies to confirm a preventive and/or therapeutic efficacy against both influenza virus H1N1 and SARS-CoV-2 infections.

Viral pandemics cause significant morbidity and mortality. Influenza A viruses and coronaviruses are among the major human threats due to the presence of an important animal reservoir and the ability of both viruses to cross the species barrier via mutation and reassortment or recombination. The ongoing SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) pandemic unveiled the inability to develop specific antivirals and vaccines in a sufficiently short time frame. Although a limited circulation of influenza virus in the 2020–2021 season was achieved through social distancing and lock-down measures, in the coming years co-infection of SARS-CoV-2 and influenza might contribute to the severity of SARS-CoV-2 pneumonia1. Moreover, neuraminidase treatment has been shown to increase the affinity of SARS-CoV-2 for its receptor, ACE-2, and this might increase the susceptibility of influenza infected patients to SARS-CoV-2 superinfection2. This scenario highlights the urgent clinical need for broad-spectrum antiviral drugs ready to use during pandemics and epidemics.

Methylene Blue (MB) is an FDA and EMA approved drug with an excellent safety profile. Due to its antimicrobial, anti-inflammatory and antitoxic effects, photoactivated MB is used for a wide range of applications including treatment of methemoglobinemia or malaria3. Photoactivated MB is also widely used to obtain blood product preparations free of viruses such as HIV4, Ebola, Middle East Respiratory Syndrome coronavirus (MERS)5, or SARS-CoV-2 virus6. The antiviral activity appears to rely on multiple mechanisms, and is more potent for enveloped viruses7. Among other actions, MB is known to corrupt viral DNA or RNA integrity. This is due to a redox reaction in which the molecule accepts electrons on its aromatic thiazine ring, thus being reduced.

1Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland. 2Institute of Microbiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. 3Epatocentro Ticino, Lugano, Switzerland. 4Kantons spit St.Gallen, St.Gallen, Switzerland. 5Omni Drugs SA, 13 Cours des Bastions, Geneva, Switzerland. 6These authors contributed equally: Valeria Cagno, Chiara Medaglia, Erich Cerny and Caroline Tapparel. *email: eh.cerny@gmail.com; caroline.tapparel@unige.ch
different doses of the compound spanning from 2 μg/ml to 0.08 μg/ml, with 1.5 × 10^7 plaque forming units (pfu) to test the antiviral activity of the compound (Table 1).

We first asked whether MB was able to exert antiviral activity independently of visible light. We thus incubated different doses of the compound spanning from 2 μg/ml to 0.08 μg/ml, with 1.5 × 10^7 plaque forming units (pfu) of human A/Netherlands/602/2009 (H1N1), for 2 h or 20 h at room temperature and in the presence or absence of visible light. We then measured the number of infectious particles in each condition. MB exerted virucidal activity in the presence and absence of light and at both incubation times, suggesting that the compound can irreversibly inactivate a relevant enveloped respiratory virus independently of visible light (Fig. 1a,b). As more than one mechanism of action can underlie the antiviral properties of MB, we asked whether the compound would damage the H1N1 genome. We measured genome integrity by RT-qPCR in each of the above-described conditions (Fig. 1c,d). Surprisingly, the reduction of H1N1 infectiousness induced by MB did not always result in a reduction of viral genome Quantity by RT-qPCR. Only upon 20 h incubation under the light and at the highest doses, MB induced a significant decrease in viral RNA, compared to the untreated control (Fig. 1d). However, as the RT-qPCR amplicon is only ~ 105 bp, it could remain intact while longer genomic fragments may be affected by the treatment. We therefore investigated the integrity of H1N1 segments by conventional PCR, targeting the entire NP and M genes, which are 1.5 and 0.9 Kb long respectively (Fig. 1e,f). As expected, the highest tested dose of MB (2 μg/ml), caused significant degradation of these two viral segments after 20 h incubation in the light. Interestingly, partial degradation was also observed upon 20 h incubation in the darkness and upon 2 h incubation under the light, while no degradation was observed after 2 h incubation in the dark (Fig. 1e,f). These findings suggest that RNA damage caused by MB does not fully account for its antiviral activity. Overall these preliminary results prompted us to evaluate the virucidal activity of MB against SARS-CoV-2.

Hence, we incubated different doses of the drug, ranging between 50 μg/ml and 0.08 μg/ml, with 5 × 10^6 pfu of SARS-CoV-2 for 20 h in the dark and at room temperature. The results shown in Fig. 2 evidence a complete inhibition of SARS-CoV-2 replication from 50 to 10 μg/ml and a 3.05 log reduction at 0.08 μg/ml, the lowest dose tested (Fig. 2a). Of note Jin et al. observed no virucidal activity of MB against SARS-CoV-2 when administered for 40 min in the dark. We thus performed additional experiments incubating MB and the virus for 2 h or 4 h and evidenced a statistically significant effect at the 2 h incubation time (Fig. 2b). This effect was however lower compared to that observed at 20 h incubation (5.3 log reduction after 2 h treatment with 20 μg/ml and 3.6 log with 2 μg/ml).

Subsequently we evaluated the possible combinatorial activity of MB and immunoglobulins present in the serum of a convalescent individual. Preliminary tests were conducted to identify the optimal serum dilution able to neutralize the virus and evidenced a 4.15 log decrease in presence of 1:16 dilution, a 2.3 log decrease in presence of 1:80 dilution, and absence of neutralization at lower serum dilutions. In order to be able to evaluate any additive effect, the serum was diluted 1:80 for further experiments. 5 × 10^6 pfu of SARS-CoV-2 were incubated with 5% human A/Netherlands/602/2009 (H1N1) serum, and MB at 2 μg/ml.

Table 1. Assessment of MB toxicity. *Cell viability was measured 48 h after treatment.
Figure 1. Assessment of MB antiviral activity on human H1N1. MB was incubated with H1N1 virus A/Netherlands/602/2009 (1.5 \times 10^7 pfu) for 2 h or 20 h in the darkness (a, c) or in the presence of light (b, d). At the end of the incubation, mixtures were serially diluted and added for 1 h at 37 °C on MDCK cells (a) and (b). Mixtures were then removed and the cells were overlaid with medium containing 0.8% agarose and TPCK trypsin 1 µg/ml. At 48 h post infection (hpi) the cells were fixed in order to count the plaques and determine the viral titer in each experimental condition. In parallel, viral RNA was quantified by RT-qPCR (c, d) and viral genome integrity was assessed by PCR amplification of the NP (e) and M (f) viral segments. In (e) and (f) only the “UT” and “MB 2 µg/ml” conditions were examined. Results are mean and SD of two independent experiments. 2 µg/ml (6.25 µM), 0.4 µg/ml (1.25 µM), 0.08 µg/ml (0.25 µM). UT = untreated. **p < 0.01, ***p < 0.001, ****p < 0.0001.

for 20 h in the dark with three different doses of MB in presence or absence of diluted convalescent serum. The results (Fig. 2c) evidence a partial additive effect of MB and convalescent sera, with a complete inhibition of viral infectivity when combining MB (up to 0.4 µg/ml) and serum. To rule out the possibility that serum factors other
than anti-SARS-CoV-2 antibodies could enhance the action of MB, we also tested MB in combination with a non-immune control serum, which showed no anti-SARS-CoV-2 activity alone nor potentiation of MB effect (Supplementary Fig. S1). To further verify the mechanism of action of MB in the dark against SARS-CoV-2, we performed RT-qPCR on the samples incubated for 2 h and 4 h. Despite the logarithmic decrease in viral infectivity (Fig. 2b), no decrease of viral RNA was evidenced by RT-qPCR (Fig. 2d).

Finally, we assessed the efficacy of MB for therapeutic use. We thus tested whether MB was able to reduce the viral yield in cells previously infected with SARS-CoV-2. The treatment was administered at 4 or 24 hpi and the virus released by the infected cells was measured titrating the culture supernatants at 48 hpi. In both conditions we observed viral inhibition in a dose–response manner (Fig. 3) with an EC50 of 0.11 µg/ml at 4 hpi and of 0.13 µg/ml at 24 hpi.

Discussion
Here we show broad-spectrum virucidal activity of MB in absence of light activation, against both H1N1 influenza virus and SARS-CoV-2 after incubation times of 2, 4 or 20 h. In previous studies, no antiviral activity was observed after shorter incubations (40 min) in absence of light. However, in these works, the evaluation of viral titer was done with qPCR and not by measuring infectivity. The activity of the compound in absence of UV-activation is thus suggestive of a different mechanism of action than that reported in presence of UV light or slower kinetics. This hypothesis is further sustained by the lack of H1N1 NP or M RNA decrease and the detection of both H1N1 and SARS-CoV-2 by RT-qPCR after a 2 h incubation with MB in the darkness (Figs. 1d and 2d), which is in line with previous reports. We highlight that the antiviral activity of MB is enhanced in combination with convalescent serum, and that such effect is specifically due to the presence of immunoglobulins against Sars-Cov-2. This suggests that the compound could not only be effective in infected patients, but also that its efficacy could be further increased by immune serum.

A limitation of our study with SARS-CoV-2 is that the experiments are performed in Vero-E6 cell line where other drugs, such as hydroxychloroquine, were reported to exert antiviral activity, however without showing efficacy in clinical trials. Nevertheless, in those cases the drug interfered with viral replication inside the cell,
while MB acts also on extracellular viral particles. Therefore, we do not expect to observe such a discrepancy when going into clinical trials.

A recent French publication on a cohort of 2500 end stage cancer patients treated with MB during the first wave of Covid-19 mentions a possible protective role of MB against respiratory viruses, as in this cohort there were no reported cases of influenza or SARS-CoV-2 infections. Another report describes a possible complementary effect of MB in vitro on the SARS-CoV-2 Spike–ACE2 protein–protein interaction. The proposed mechanism of action is mediated by the binding of MB on the cells and not on the virus. The experiments were performed in a different experimental setting than ours, by pre-treating the cells with MB and subsequently infecting them with SARS-CoV-2. Lastly, an additional study compared in vitro the median Effective Concentration (EC50) of 3 drugs against SARS-COV-2, when administered 4 h before infection. MB was the most efficient antiviral drug with an EC50 of 0.30 ± 0.03 µM. This study did not focus on the activity in absence or presence of light, nor in measuring the viral inactivation. The drug was added 4 h before infection and left on cells for the entire experiment, and the infectivity was evaluated through RT-qPCR. The EC50 determined was however in line with our experiments in which we added MB after infection (Fig. 3), validating our results.

In view of the wide variety of singlet oxygen driven chemical reactions corroding nucleic acids and proteins, one is surprised by the well documented absence of severe side effects of MB, even at doses up to 5 mg/kg. This may be linked to the fact, that the body’s immune system uses MB for its own purposes. It is known that antibodies have, close to their binding site, a catalytic site capable of producing singlet oxygen in the presence of water. Riboflavin, also known as Vitamin B2 is another efficient singlet oxygen producing compound. It seems reasonable to assume that mammals have developed so far unknown control mechanisms to keep singlet oxygen collateral damages at bay.

Altogether, our results support the interest of testing MB in clinical studies to confirm a preventive or therapeutic efficacy, alone or combined with immune sera, against two major public health concerns: influenza virus and SARS-CoV-2. Further experiments will be required to fully understand the different antiviral mechanisms of action of MB against these two enveloped viruses. Based on previously published data, MB might inactivate viruses limiting viral replication and spread beyond the upper respiratory tract. In addition, its anti-inflammatory activity may lower the side effects linked to the host response.

**Materials and methods**

**Compound and convalescent serum.** Methylene blue (Methylthonium chloride solution) was purchased from ProVepharm. A convalescent or a control serum, respectively tested positive or negative for IgG against SARS-CoV-2 by ELISA, were isolated from blood collected in serum separator tubes. Within 1 h from collection, sera were isolated by centrifuging the blood at 2500 RPM for 15 min. The sera were aliquoted and stored at −80 °C.

**Cells and virus.** MDCK and (ATCC CCL34) cells and Vero C1008 (clone E6) (ATCC CRL-1586) cells (kindly provided by Prof Gary Kobinger from the University of Laval), were propagated in DMEM High Glucose + Glutamax supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptavidin (pen/strep).

SARS-CoV-2/Switzerland/GH9786/2020 was isolated from a clinical specimen in the University Hospital of Geneva in Vero-E6. Cells were infected and supernatant was collected 3 days post infection, clarified, aliquoted and frozen at −80 °C before titration by plaque assay in Vero-E6.

Human H1N1 virus A/Netherlands/602/2009, clade 1A.3.3.2, [Fludb entry CY148018] was a gift from Prof. Mirco Schmolke (University of Geneva) and was cultivated and titrated in MDCK cells by plaque assay.
Toxicity assay. Vero-E6 and MDCK cells (13,000 and 20,000 cells per well respectively) were seeded in 96-well plate one day before the assay. For toxicity evaluation in Vero-E6 methylene blue was serially diluted 1:2 in DMEM supplemented with 5% FBS and added on cells for 1 h, followed by a washout and the addition of DMEM supplemented with 5% FBS for additional 48 h hours. Alternatively, the dose range of MB was added on the cells for 48 h. The toxicity evaluation in MDCK cells was performed in serum free DMEM supplemented with 0.2 μg/ml of TPCK-Trypsin (Sigma), using the same MB dose-range and times of treatment applied to Vero-E6. MTS reagent (Promega) was added on cells for 3 h at 37 °C according to manufacturer instructions, subsequently absorbance read at 570 nm. Percentages of viability were calculated by comparing the absorbance in treated and untreated wells. 50% cytotoxic concentration (CC50) were calculated with Prism 8 (GraphPad).

Plaque assay. Vero-E6, 100000 cells per well, were seeded in 24-well plate one day before the assay. Serial dilutions of SARS-CoV-2 were added on cells in a final volume of 200 μl for 1 h at 37 °C. After infection Vero-E6 cells were washed and overlaid with 0.8% Avicel rc581 in medium supplemented with 5% FBS. MDCK cells 500000 cells per well, were seeded in 6-well plate 24 h in advance. Serial dilutions were added on cells in a final volume of 500 μl for 1 h at 37 °C. MDCK monolayers were then washed and overlaid with 0.8% agarose in medium supplemented with TPCK trypsin 1 μg/ml.

Two days after infection, cells were fixed with paraformaldehyde 4% and stained with crystal violet solution containing ethanol. Plaques were counted.

Inhibition assay. H1N1 (1.5 × 107 pfu) or SARS-CoV-2 (5 × 106 pfu) were incubated at room temperature in the dark (in an opaque stainless-steel box) or under visible light, in a final volume of 100 μl, with different dilutions of MB for 2 or 20 h. The infection mixtures were then serially diluted (1:10 factor) and added for 1 h at 37 °C on the respective host cell lines. The residual infectivity was evaluated by plaque assay as described in the previous paragraph. The residual infectivity of the different conditions was calculated. Statistical analysis was done with Prism software (GraphPad) comparing the different conditions.

Neutralization assay. SARS-CoV-2 (5 × 106 pfu) was incubated at room temperature in the dark for 20 h in a final volume of 400 μl, with different dilutions of immune serum. The infection mixtures were then serially diluted (1:10 factor) and added for 1 h at 37 °C on the respective host cell lines and subjected to plaque assay as described in the paragraph above. The same experiments were conducted in presence of immune serum and non immune serum at dilution 1:80 in presence or absence of different concentrations of MB.

RT-qPCR analysis. H1N1 (1.5 × 107 pfu) was incubated at room temperature in the dark (in an opaque stainless steel box) or under visible light, in a final volume of 100 μl, with different dilutions of MB for 2 or 20 h. SARS-CoV-2 (5 × 106 pfu) was incubated in the dark with 2 or 20 μg/ml of MB for 2 or 4 h. Viral RNA was extracted with EZNA viral extraction kit (Omega Biotek) and quantified by using RT-qPCR (Table 2) with the QuantiTect kit (Qiagen) in a StepOne ABI Thermocycler.

PCR analysis. Viral RNAs were isolated from H1N1 (1.5 × 107 pfu) incubated at room temperature in the dark (in an opaque stainless-steel box) or under visible light, in a final volume of 100 μl, with MB (2 μg/ml) for 2 or 20 h. Samples were then reverse transcribed. The RT reaction was performed with a mix composed of First Strand Buffer 5x (Invitrogen), H2O Rnase free, Superscript III RT/Platinum Taq Mix (Invitrogen), 0.1 M DTT (Invitrogen), dNTPs (25 mM), Protector RNase inhibitor (40U/ul) (Roche) and Random hexamers (50ug/ul) (Invitrogen).

Viral gene segments were then amplified from the viral cDNA using a master mix composed of 10X PCR Rxn buffer (-MgCl2) (Invitrogen), 50 mM MgCl2 (Invitrogen), H2O Rnase free, Platinum Taq DNA polymerase (5U/ul) (Invitrogen), dNTPs (10 mM) and M13-tailed primers specific for the M and NP H1N1 segments (Table 3). The length and the quality of the amplified fragments were verified by electrophoresis in an agarose gel 1% with 4 ul of Sybr-safe.

Viral yield reduction assay. Vero-E6 cells (100,000 cells per well) were seeded in 24-well plate. Cells were infected with SARS-CoV-2 (MOI, 0.005 pfu/cell) for 4 h at 37 °C. The monolayers were then washed and overlaid.
with medium supplemented with 5% FBS containing serial dilutions of compound, alternatively the compound was added 24 hpi. Supernatants were harvested 48 hpi and titrated on Vero-E6 cells.

**Statistical analysis.** Where possible, half-maximal antiviral effective concentration (EC50) values were calculated by regression analysis using the dose-response curves generated from the experimental data using Prism software (GraphPad). The 50% cytotoxic concentration (CC50) was determined using logarithmic viability curves. Two-way or one-way ANOVA, followed by Dunnet’s multiple comparison test, was used to assess the statistical significance of the differences between treated and untreated samples. Significance was set at the 95% level.

**Ethical authorization.** Written informed consent was obtained from the subjects involved and the research protocol was approved by the local ethics committee (commission cantonale d’éthique de la recherche CCER de Genève) and performed in accordance with relevant regulations and with the Declaration of Helsinki.

**Data availability**

Raw data are available upon request to the authors.

Received: 23 December 2020; Accepted: 8 June 2021
Published online: 12 July 2021

**References**

1. Yu, C. et al. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study. *J. Med. Virol.* https://doi.org/10.1002/jmv.26260 (2020).
2. Chu, H. et al. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. *Nat. Commun.* 12, 134. https://doi.org/10.1038/s41467-020-20457-w (2021).
3. Nedu, M. E., Tertis, M., Cristea, C. & Georgescu, A. V. Comparative study regarding the properties of methylene blue and proflavine and their optimal concentrations for in vitro and in vivo applications. *Diagnetics* https://doi.org/10.3390/diagnostics10040223 (2020).
4. Eickmann, M. et al. Elucidation of the HIV-1 virucidal mechanism of methylene blue photosensitization and the effect on primary isolates. *J. Med. Virol.* 62, 423–425 (2000).
5. Eickmann, M. et al. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. *Transfusion* 58, 2202–2207. https://doi.org/10.1111/trf.14652 (2018).
6. Liu, J. et al. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19. *BMC Infect. Dis.* 21, 357. https://doi.org/10.1186/s12879-021-05993-0 (2021).
7. Lambrecht, B., Mohr, H., Knuever-Hopf, J. & Schmitt, H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. *Vox Sang* 60, 207–213. https://doi.org/10.1111/1.j.1423-4010.1991.tb00907.x (1991).
8. Schneider, J. E. Jr et al. Potential mechanisms of photodynamic inactivation of virus by methylene blue. I. RNA-protein crosslinks and other oxidative lesions in Q beta bacteriophage. *Photochem. Photobiol.* 67, 350–357 (1998).
9. Bachmann, R., Knuever-Hopf, J., Lambrecht, R. & Mohr, H. Target structures for HIV-1 inactivation by methylene blue and light. *J. Med. Virol.* 47, 172–178. https://doi.org/10.1002/jmv.1890470211 (1995).
10. Lu, G. et al. Efficacy and safety of methylene blue in the treatment of malaria: A systematic review. *BMC Med.* 16, 59. https://doi.org/10.1186/s12916-018-1045-3 (2018).
11. Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Disov.* 6, 16. https://doi.org/10.1038/s41421-020-0156-0 (2020).
12. Pan, H. et al. Repurposed antiviral drugs for COVID-19: Interim WHO SOLIDARITY trial results. medRxiv https://doi.org/10.1101/2020.05.20.2009817 (2020).
13. Henry, M., Summa, M., Patrick, L. & Schwartz, L. A cohort of cancer patients with no reported cases of SARS-CoV-2 infection: The possible preventive role of Methylene Blue. *Substantia* https://doi.org/10.13128/Substantia-688 (2020).
14. Bojadzic, D., Alcazar, O. & Buchwald, P. Methylene Blue inhibits in vitro the SARS-CoV-2 Spike—ACE2 protein-protein interaction: A mechanism that can contribute to its antiviral activity against COVID-19. *bioRxiv* https://doi.org/10.1101/2020.08.29.273441 (2020).
15. Gendrot, M. et al. Methylene blue inhibits the replication of SARS-CoV-2 in vitro. *Int. J. Antimicrob. Agents* https://doi.org/10.1016/j.ijantimicag.2020.106202 (2020).
16. Datta, D., Vaidhe, N., Xu, X. & Goddard, W. A. 3rd. Mechanism for antibody catalysis of the oxidation of water by singlet dioxygen. *Proc. Natl. Acad. Sci. USA* 99, 2636–2641. https://doi.org/10.1073/pnas.052709399 (2002).
17. Huang, R., Choe, E. & Min, D. B. Kinetics for singlet oxygen formation by riboflavin photosensitization and the reaction between riboflavin and singlet oxygen. *J. Food Sci.* 69, C726–C732. https://doi.org/10.1111/j.1365-2612.2004.tb09924.x (2004).
18. Seibert, C. W. et al. Reombinant Igα is sufficient to prevent influenza virus transmission in guinea pigs. *J. Virol.* 87, 7793–7804. https://doi.org/10.1128/JVI.00979-13 (2013).

| Gene | Primer | Binding position | Sequence* |
|------|--------|-----------------|-----------|
| M    | Forward| 1–21            | TGAAAAACGAGCCAGTATGAGTCTCTAACGGAGGTC |
| M    | Reverse| 959–982         | CAGAAAAACAGCTATGACCTTAGCTACTGCTATGTTGCAAA |
| NP   | Forward| 1–20            | TGTTTTTTCGAGGAGCTGATGGCGTCTCAGGACCC |
| NP   | Reverse| 1474–1494       | CAGTAAATGCACTGAACCGTACCTACGCTCNTCTTCG |

Table 3. Primers used to amplify gene segments of A(H1N1)pdm09 virus. *The sequence of the M13 tail is indicated in bold.*
Acknowledgements
We thank Isabella Eckerle for providing us the SARS-CoV-2 virus.

Author contributions
Conceptualization, E.C., T.C. and A.C.; methodology, V.C., C.M. and C.T.; investigation, V.C., C.M. and A.C.Z.; resources, C.T.; data curation, V.C. and C.M.; writing—original draft preparation, E.C. V.C. and C.T.; writing—review and editing, C.M.; supervision, C.T.; funding acquisition, C.T. All authors have read and agreed to the published version of the manuscript.

Funding
This research was funded by Fondation des HUG and Carigest Foundation to C.T.

Competing interests
E.C., T.C., A.C., C.T. have a Swiss patent application pending covering the use of Methylene blue as an anti-viral drug for SARS-CoV-2. The other authors declare no conflict of interest.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-92481-9.

Correspondence and requests for materials should be addressed to E.C. or C.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021